THOMAS WIND: Open Payments
NPI 1508982265 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,659 in 146 payments from 20 companies in 2025. Trend: 2023 $3,747 · 2024 $2,921 · 2025 $2,659
Food & beverage: $2,659
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $546 |
| ABBVIE INC. | 27 | $333 |
| Axsome Therapeutics, Inc. | 16 | $249 |
| Collegium Pharmaceutical, Inc. | 12 | $221 |
| Neurocrine BioSciences, Inc. | 10 | $210 |
| Vanda Pharmaceuticals Inc. | 10 | $171 |
| E.R. Squibb & Sons, L.L.C. | 1 | $114 |
| Janssen Pharmaceuticals, Inc | 5 | $110 |
| Teva Pharmaceuticals USA, Inc. | 4 | $86 |
| Alkermes, Inc. | 4 | $82 |
Products named: CAPLYTA, VRAYLAR, Auvelity, Jornay PM, INGREZZA, FANAPT, REXULTI, COBENFY.
Industry payments across PA — which companies pay providers there.
